Brad Burd
About Brad Burd
Brad Burd is Chief Legal Officer and Corporate Secretary of GoHealth (since February 2024), having joined the company in 2011 and previously served as General Counsel (2011–Feb 2024) and Interim Corporate Secretary (2019–July 2020). He oversees legal affairs including compliance, government relations, commercial, and corporate governance; prior to GoHealth, he worked in the Chicago offices of two national law firms and represented GoHealth as outside counsel; he holds a B.S. in Finance from Miami University and a J.D. from the University of Cincinnati College of Law . GoHealth’s recent operating trajectory shows strengthening scale and profitability: revenue grew from FY 2023 to FY 2024 and EBITDA improved over the same period (see table below) . The company’s pay-versus-performance disclosure also shows a marked improvement in net income from FY 2023 to FY 2024 and relatively stable TSR value of a hypothetical $100 investment over the same period .
Company performance during Burd’s current executive tenure:
| Metric (USD) | FY 2023 | FY 2024 |
|---|---|---|
| Revenues | $734.7M | $798.9M |
| EBITDA | $28.95M | $91.64M* |
*Values retrieved from S&P Global.
Additional pay-versus-performance indicators:
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Net Income (Millions) | $(63.26) | $(2.93) |
| Value of $100 Investment (TSR) | $23.47 | $23.55 |
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| GoHealth | Chief Legal Officer & Corporate Secretary | Feb 2024–Present | Leads legal, compliance, government relations, commercial, and governance matters . |
| GoHealth | General Counsel | 2011–Feb 2024 | Directed legal through IPO (2020) and multiple corporate phases . |
| GoHealth | Interim Corporate Secretary | 2019–July 2020 | Supported governance and disclosure during public-company transition . |
| Two national law firms (Chicago) | Attorney (outside counsel to GoHealth) | Prior to 2011 | Advised GoHealth; built industry and company-specific legal expertise . |
External Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| ALMIA (Alliance of Licensed Medicare Insurance Agencies) | President | 2024–Present | Convened Medicare AEP-focused industry forum; promoted best practices across carriers and brokers . |
Fixed Compensation
- Individual compensation for Brad Burd (salary, bonus, perquisites) is not disclosed in the company’s 2025 proxy; only NEOs (CEO, CFO, COO) are reported .
- The company offers executive health benefits to senior officers and states no tax gross‑ups for NEOs; these reflect broader program design but are not itemized for the CLO .
Performance Compensation
- The proxy details the 2024 Annual Bonus Plan for NEOs with five weighted metrics (CFO and COO included): Cash from Operations (25%), Adjusted EBITDA ex-LTV lookbacks (25%), Enrollments & Transfers (20%), Captive Core Conversion (20%), and Revenue Expansion (10%); payout outcomes were 145% of target for NEOs based on performance dispersion by metric .
- There is no Brad-specific disclosure of target/actual bonus metrics, equity mix, or vesting schedules in the proxy (he is not an NEO) .
Equity Ownership & Alignment
- Individual beneficial ownership for Brad Burd is not listed; the ownership table covers directors, NEOs, and totals for all directors and executive officers as a group .
- Hedging is prohibited for directors, officers, employees, and their controlled entities (e.g., prepaid forwards, swaps, collars, exchange funds); the policy is filed with the 10‑K .
- The company maintains a Dodd‑Frank-compliant clawback policy requiring recoupment of incentive compensation from covered executive officers in the event of certain restatements .
- The company’s 2020 Incentive Award Plan (amended) continues to underpin equity compensation for executives; an additional share increase under the plan was approved by stockholders in June 2025 .
Employment Terms
- No Brad-specific employment agreement or severance/change‑in‑control terms are disclosed in the 2025 proxy or related materials; employment agreement summaries are provided only for the CEO, CFO, and COO .
- As a governance backdrop, GoHealth operates as a “controlled company” under Nasdaq rules, availing certain committee-composition exemptions .
Investment Implications
- Alignment and retention: Long-tenured insider (since 2011) in a mission‑critical control role; hedging ban and clawback policy support alignment, though lack of disclosed pledging restrictions is a monitoring point .
- Data transparency risk: As a non‑NEO, Brad’s individual pay mix, targets, and vesting schedules are not disclosed; investors should monitor Form 4s and future proxies for insider selling pressure and equity realizable pay clarity .
- Governance context: Controlled company status and compensation committee composition (founder chair plus independents) warrant continued oversight of pay rigor and change‑in‑control protections across the executive team .
- Execution track record linkage: Company FY 2024 revenue and EBITDA improved versus FY 2023, while net loss narrowed materially; these operational gains underpin a constructive backdrop for legal/compliance leadership effectiveness during AEP and integration initiatives .
- Shareholder sentiment: 2025 say‑on‑pay passed, and stockholders approved additional equity plan shares—indicating support for compensation design and talent retention, but implying ongoing equity issuance and potential dilution trade‑offs .